37 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Oct 2028
Next term end
22
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2031 · High confidence
Also notable
Ends Apr 2035 · High confidence
Also notable
Ends Mar 2035 · High confidence
Tissue Occluding Agent Comprising an Ieikieikieiki Peptide
US 10,576,123
Cited by 33 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2031.
Sterilization and Filtration of Peptide Compositions
US 10,369,237
Cited by 30 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2035.
Self-Assembling Peptide Compositions
US 10,654,893
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 14, 2026The maintenance fee for Syringe and Syringe Set (US 10,286,200) comes due Nov 14, 2026. Unpaid by May 14, 2027, it lapses early.
- 3 fees due Feb 6 to 28, 2027 · next Feb 6
- 1 fee due Mar 15, 2027The maintenance fee for Transfection Agent (US 9,133,484) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Tissue Occluding Agent Comprising an Ieikieikieiki Peptide (US 11,801,281) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 3 fees due Sep 3 to 24, 2027 · next Sep 3
- 1 fee due Oct 26, 2027The maintenance fee for MicroRNA-Based Methods and Assays for Osteosarcoma (US 9,322,016) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 22 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Sterilization of Self-Assembling Peptides by Irradiation | 4 in force | to Mar 2041 |
| Ionic Self-Assembling Peptides | 3 in force | to Jan 2040 |
| Sterilization and Filtration of Peptide Compositions | 3 in force | to Nov 2035 |
| MicroRNA-Based Methods and Assays for Osteosarcoma | 3 in force | to Sep 2032 |
| Tissue Occluding Agent Comprising an Ieikieikieiki Peptide | 3 in force | to Nov 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D714,935 | Adapter for Connecting a Needle to a Syringe held by Fuso Pharmaceutical Industries, Ltd. and 3-D Matrix, Ltd. In force · High confidence | In force | High confidence | |
| US D731,647 | Syringe held by Fuso Pharmaceutical Industries, Ltd. and 3-D Matrix, Ltd. In force · High confidence | In force | High confidence | |
| US 11,801,281 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide In force · High confidence | In force | High confidence | |
| US D751,726 | Package held by Fuso Pharmaceutical Industries, Ltd. and 3-D Matrix, Ltd. In force · High confidence | In force | High confidence | |
| US 10,576,123 | Tissue Occluding Agent Comprising an Ieikieikieiki Peptide In force · High confidence | In force | High confidence | |
| US 9,133,484 | Transfection Agent held by 3-D Matrix, Ltd. and Nippon Medical School Foundation In force · High confidence | In force | High confidence | |
| US 10,596,225 | Tissue Occluding Agent Comprising An IEIKIEIKIEIKI Peptide In force · High confidence | In force | High confidence | |
| US 10,905,708 | Microrna-Based Methods and Assays for Osteocarcinoma In force · High confidence | In force | High confidence | |
| US 11,260,072 | MicroRNA-based methods and assays for osteocarcinoma In force · High confidence | In force | High confidence | |
| US 9,322,016 | MicroRNA-Based Methods and Assays for Osteosarcoma In force · High confidence | In force | High confidence |
Also on record, not counted in the 37: 2 patents in force now held by others · 4 patents ended · 13 applications pending · 35 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.